The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Menin inhibitors in AML: providing options for patients with NPM1 mutation and KMT2A rearrangement
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, briefly discusses the rationale behind using menin inhibitors to treat patients with acute myeloid leukemia (AML), highlighting the important role of these agents in patients with NPM1 mutation and KMT2A rearrangement. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
